Clinical Trial Detail

NCT ID NCT02138292
Title A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Texas Southwestern Medical Center
Indications

melanoma

Therapies

Digoxin + Trametinib

Age Groups: adult

Additional content available in CKB BOOST